Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200-a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and ...
Outlook Therapeutics, Inc.: Outlook Therapeutics Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial
ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant inducement transaction expected to result in up to $20 ...